We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Paired Laboratory Tests Predict Vein Graft Occlusion

By LabMedica International staff writers
Posted on 15 Mar 2011
A blood test for platelet clumping velocity and another for a clumping chemical byproduct can predict whether coronary artery bypass grafting will be successful. More...


The aggregation of platelets and their activation in plasma and blood can be assessed and correlated with the levels of a chemical found in the urine to saphenous vein graft (SVG) occlusion.

A team of cardiologists at Johns Hopkins School of Medicine, (Baltimore, MD, USA), examined platelet activation 3 days and 6 months after coronary artery bypass graft surgery in 229 subjects receiving aspirin monotherapy.

The cardiologists used a platelet function analyzer (PFA), and measured closure time (CT) using collagen/epinephrine agonist cartridge and collagen/adenosine diphosphate (CADP) agonist cartridge (Accumetrics, Inc., San Diego, CA, USA). Thromboxane A2 (TXA2) generation was quantified by measuring the concentration of its stable metabolite 11-dehydro-thromboxane B2 (UTXB2) in urine by enzyme-linked immunosorbent assay (ELISA) and expressed as a ratio to urinary creatinine.

The results from the Platelet Function Analyzer-100 (PFA-100; Siemens Healthcare Diagnostics, Newark, DE, USA), showed that those who ranked in the quarter with the slowest blood-clotting times had an 11% vein graft failure rate, while those whose blood clotted fastest had a 28% risk. Tests for UTXB, a highly reactive chemical whose action is normally suppressed by aspirin, were equally linked to vein graft failure. Study participants in the quartile with the lowest amounts of UTXB had a 12% likelihood of one or more veins occluding, while in the quartile with the highest amounts of UTXB, the rate was 29%. When results of both tests were combined, patients with the "most-sticky" platelets and highest UTXB levels had a nearly sevenfold increased risk of vein graft failure, compared to those who had the "least-sticky" platelets and lowest UTXB levels.

Jeffrey Rade, MD, the senior investigator, said, "These two tests offer physicians new tools for early detection of bypass patients at greatest risk of vein graft failure, giving them advance warning and, potentially, buying time to try drug or surgical therapies that might either slow down or reverse the narrowing and buildup of plaque and dead cells inside the grafted vein".

The authors concluded that aspirin-insensitive thromboxane generation measured by UTXB2 and shear-dependent platelet hyper-reactivity measured by Platelet Function Analyzer-100 CADP CT are novel independent risk factors for early SVG thrombosis after coronary artery bypass graft surgery. The study was published March 1, 2011, in the Journal of the American College of Cardiology.


Related Links:

Johns Hopkins School of Medicine
Accumetrics, Inc.
Siemens Healthcare Diagnostics



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.